Damora Therapeutics Inc. (DMRA)
DMRA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | DMRA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Denmark |
| IPO year | 2020 |
| SEC CIK | 0001800315 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
Foreign filer: no machine-readable annual figure in SEC data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "If we are unable to raise additional capital when needed, that could raise substantial doubt about our ability to continue as a going concern." | 10-Q 2026-11-04 |
| Cash and burn | $349.7M cash; operating cash flow -$14.8M a quarter. | Report 2026-09-30 |
| Shares outstanding | 61,904,742 (2026-11-02); 1,327,212 a year earlier; 27,112,697 three years earlier. 3y figure adjusted for split (1-for-25 overall). | Cover page 2026-11-02 |
| Reverse splits, 3 years | 1; latest 1-for-25 on 2024-08-30 | Source 2024-08-30 |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-02-11 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | EY Godkendt Revisionspartnerselskab, Copenhagen, Denmark; changed auditors 1 time in 24 months | 8-K 4.01 2026-04-20 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $253K, sold $31K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$32.0M | -$17.2M | $349.7M | No debt tags | Needs four quarters | 10-Q 2026-11-04 |
| Q2 2026 2026-06-30 | Not filed | -$31.2M | -$21.9M | $540.5M | No debt tags | Needs four quarters | 10-Q 2026-08-10 |
| Q1 2026 2026-03-31 | Not filed | -$27.8M | -$20.6M | $532.9M | No debt tags | Needs four quarters | 10-Q 2026-05-12 |
| Q4 2025 2025-12-31 | Not filed | -$200.7M | $566K | $257.6M | No debt tags | Needs four quarters | 10-K 2026-03-19 |
| Q3 2025 2025-09-30 | Not filed | -$3.1M | -$2.6M | $7.6M | No debt tags | Needs four quarters | 10-Q 2026-11-04 |
| Q2 2025 2025-06-30 | Not filed | -$3.4M | -$2.2M | $10.2M | No debt tags | Needs four quarters | 10-Q 2026-08-10 |
| Q1 2025 2025-03-31 | Not filed | -$2.5M | -$2.4M | $11.9M | No debt tags | Needs four quarters | 10-Q 2026-05-12 |
| Q4 2024 2024-12-31 | Not filed | -$6.7M | -$4.9M | $14.2M | No debt tags | Needs four quarters | 10-K 2026-03-19 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | POS AM | 2026-08-10 |
| Latest annual report | 10-K | 2026-03-19 |
| Latest quarterly / interim | 10-Q | 2026-11-04 |
| Latest current report | 8-K | 2026-07-20 |
| Latest proxy | DEF 14A | 2026-04-29 |
Source: SEC EDGAR submissions feed, 353 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -8.9% |
| 1 month | +16.4% |
| 3 months | -29.7% |
| Year to date | -6.1% |
| 1 year | -22.4% |
| From 52-week high | -36.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| LBRX | LB Pharmaceuticals Inc | $42.99 | -0.05% | $1.4B |
| URGN | UroGen Pharma Ltd. | $28.10 | +7.33% | $1.4B |
| PAHC | Phibro Animal Health Corporation | $35.02 | -2.64% | $1.4B |
| TYRA | Tyra Biosciences Inc. | $19.74 | -1.42% | $1.4B |
| ANAB | AnaptysBio Inc. | $45.73 | -1.12% | $1.4B |
| NUVB | Nuvation Bio Inc. | $3.84 | -3.76% | $1.4B |
| GENB | Generate Biomedicines Inc. | $10.49 | -13.09% | $1.4B |
| NBTX | Nanobiotix S.A. | $28.54 | -6.90% | $1.5B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier